Providing Market Intelligence for 40 Years

In The News

Roku IPO a Success, Despite Gaining Little Revenue From YouTube or Netflix

Amazon, for example, is able to sell its own TV streaming products as well as market and promote those products more prominently on its official website. But user trends favor the company’s services. About 80 percent of millennials say they watch or have access to streaming services, so that’s good news for the company.

“Over the past two-and-a-half years, Roku has expanded their product lines, evolved their platform business with smart-TV makers, and continued to build out its advertising business,” Brett Sappington, director of research at consulting firm Parks Associates, told the LA Times. “A platform-based approach and their advertising business will be keys to their future revenues and success.”

From the article "Roku IPO a Success, Despite Gaining Little Revenue From YouTube or Netflix" by Stephen Jordan.

Previously In The News

AT&T gooses $45 prepaid plan with cheaper iPhones

And, as a recent report from Parks Associates noted, consumers are increasingly drawn to the simplified pricing offers in prepaid. The firm said that “currently postpaid carriers are starting to explo...

59% of broadband-enabled UK households now access video content online

The proportion of UK households with broadband connections utilising the service to access online video content has reached 59%, according to new research. Parks Associates relayed their key findin...

AT&T kills Plenti loyalty program but touts ongoing Thanks campaign

Parks Associates reported last year that 60% of respondents in a survey valued a rewards program for being a loyal customers, third only to the ability to roll over unused data (66%) and free access t...

Morning Read: Pharma Changes Afoot As Valeant Courts A New CEO And Novartis U.S. Head Exits

Less than half of caregivers with a smartphone use apps aimed at caregivers, according to a report by Parks Associates. — MobiHealthNews From the article "Morning Read: Pharma Changes Afoot As Vale...